A new review highlights growing evidence that cyclin-dependent kinase (CDK) inhibitors—already used in over a million breast cancer patients—could benefit other cancers through novel drug combinations ...
Cyclin-dependent kinase (CDK)4/6 inhibitors are approved for the treatment of breast cancer, and they have more recently been used in patients with well ...
Insilico Medicine Inc. has patented new cyclin-dependent kinase 12 (CDK12)/cyclin K and/or CDK13 inhibitors reported to be useful for the treatment of cancer, particularly triple-negative breast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results